Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 1Salivary Gland Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1

Interventions

Fluorouracil 34Cisplatin 34Radiotherapy 30Oxaliplatin 30Paclitaxel 22pembrolizumab 20Irinotecan 20Docetaxel 20Leucovorin 19Capecitabine 16Cetuximab 11Carboplatin 11Bevacizumab 11Radiation 10Surgical Procedures, Operative 9Trastuzumab 8Panitumumab 6Epirubicin 6Neoadjuvant Therapy 5Esophagectomy 4Erlotinib Hydrochloride 4Chemotherapy, Adjuvant 4tisotumab vedotin 3durvalumab 3Sunitinib 3Microarray Analysis 3Immunohistochemistry 3Gene Expression Profiling 3Gemcitabine 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Esophageal Neoplasms × amivantamab × Clear all
NCT04945733 2024-09-19

A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

Janssen Pharmaceutical K.K.

Phase 2 Terminated
62 enrolled 28 charts
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡